Cambridge, MA-based Curis (NASDAQ: [[ticker:CRIS]]) said today it will receive a $3 million cash payment from its partner, Genentech (NYSE: [[ticker:DNA]]). The payment is due because Genentech is starting a clinical trial among patients with ovarian cancer. Researchers will look at 100 patients with the disease, taking either a placebo or GDC-0449, an oral pill made to block the action of the Hedgehog pathway, which is thought to be critical to the survival of cancer cells and their ability to resist chemotherapy.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
